Global Assets Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,010
Closed -$222K – 314
2026
Q2
$222K Sell
4,010
-350
-8% -$18.4K 0.05% 306
2026
Q1
$207K Buy
4,360
+10
+0.2% +$527 0.06% 209
2025
Q4
$228K Buy
+4,350
New +$261K 0.07% 255

Other funds holding CRSP

Global Assets Advisory's CRSP Position: Q3 2026 in Review

Global Assets Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 4,010 shares — an estimated $222K sold.

Global Assets Advisory first reported a position in CRSP in Q4 2025 and held it in 3 quarters. The position peaked at $228K in Q4 2025. 500 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Global Assets Advisory reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Global Assets Advisory sold 4,010 CRISPR Therapeutics shares in Q3 2026, an estimated $222K.
  • Global Assets Advisory first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 3 quarters.
  • Global Assets Advisory's CRISPR Therapeutics position peaked at $228K in Q4 2025.
  • 500 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Global Assets Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.